SNPHY (Santen Pharmaceutical Co) Cash Flow for Dividends: $-84 Mil (TTM As of Mar. 2026)


SNPHY Santen Pharmaceutical Co Ltd SNPHY
82 GF Score
Price $12.76
GF Value $10.08
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Cash Flow for Dividends?

Santen Pharmaceutical Co SNPHY -2.57% 82 Cash Flow for Dividends is $-84 Mil as of Mar. 2026. GuruFocus rates SNPHY with a GF Score™ of 82/100 and a GF Value™ of $10.08 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Santen Pharmaceutical Co's cash flow for dividends for the three months ended in Mar. 2026 was $-0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was $-84 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Santen Pharmaceutical Co's quarterly payment of dividends increased from Sep. 2025 ($-0 Mil) to Dec. 2025 ($-39 Mil) but then declined from Dec. 2025 ($-39 Mil) to Mar. 2026 ($-0 Mil).

Santen Pharmaceutical Co's annual payment of dividends declined from Mar. 2024 ($-79 Mil) to Mar. 2025 ($0 Mil) but then increased from Mar. 2025 ($0 Mil) to Mar. 2026 ($-80 Mil).

Santen Pharmaceutical Co Cash Flow for Dividends Related Terms

Santen Pharmaceutical Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Cash Flow for Dividends Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -101.15 -94.32 -79.30 0.00 -79.67

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -44.35 -0.48 -39.09 -0.43
SNPHY
82GF Score
Santen Pharmaceutical Co Ltd SNPHY
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $-84 Mil mean?
Santen Pharmaceutical Co (SNPHY) has a Cash Flow for Dividends of $-84 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Cash Flow for Dividends too high?
Santen Pharmaceutical Co's current Cash Flow for Dividends is $-84 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Cash Flow for Dividends compare to LLY and JNJ?
Santen Pharmaceutical Co's Cash Flow for Dividends of $-84 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Cash Flow for Dividends is $-84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.08, compared to a current price of $12.76 — trading 26.6% above its estimated fair value. The current Cash Flow for Dividends is $-84 Mil. Santen Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current Cash Flow for Dividends is $-84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $12.76 is trading 26.6% above its estimated GF Value™ of $10.08. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHY:

  • Cash Flow for Dividends: $-84 Mil
  • GF Value™: $10.08 vs. price of $12.76 (26.6% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges 4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
82GF Score

Get the complete analysis for SNPHY

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.76
Price
$10.08
GF Value